Search

Subscribe for email alerts

To receive MDxHealth email alerts, please fill in your contact information, select the items you would like to receive, and click the submit button.

Send me company info alerts for the following lists

Subscribe Unsubscribe

ConfirmMDx for Prostate Cancer


False Negative Biopsy Dilemma

Approximately 700,0001,2 American men receive a negative prostate biopsy result; however approximately 25%3 of these results are false-negative. Under the current standard of care, prostate biopsy procedures collect 10-12 needle biopsy cores on average, effectively sampling less than 1% of a man’s prostate. This approach leaves men at risk of occult cancer, leading to a high rate of repeat biopsies, often on cancer-free men. ConfirmMDx for Prostate Cancer addresses the unmet medical need for a clinically effective diagnostic test to address this dilemma.

ConfirmMDx for Prostate Cancer is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those who may have occult cancer. The test helps urologists rule-out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule-in high risk patients who may require repeat biopsies and potential treatment.


ConfirmMDx Field Effect

ConfirmMDx detects an epigenetic field effect or “halo” associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This epigenetic “halo” around a cancer lesion can be present despite having a normal appearance under the microscope.3

ConfirmMDx Field Effect Diagram

 

 

 

 

 

 

 

 

ConfirmMDx Clinical Utility

  • Helps you spare the vast majority of cancer-free men from unnecessary repeat biopsies.
  • Aids in the identification of high-risk men who may need a repeat biopsy and potential treatment.
  • 90% NPV in confirming negative biopsy.4,5
  • Provides prostate mapping of the results.
  • Performed on residual FFPE biopsy samples.
  •  


    ConfirmMDx Prostate Mapping (sample report)

    ConfirmMDx Mapping

     

    ConfirmMDx Clinical Validity

  • Genes and methylation technology tested on ~4,128 patients with over 42 published studies
  • Investigators from leading United States and European academic medical institutions
  •  

     

    ConfirmMDx for Prostate Cancer Chart

     

     

    Additional Information

    ConfirmMDx Specimen Requirements

    To order or for more info Call 866.259.5644 or email This e-mail address is being protected from spambots. You need JavaScript enabled to view it


    References

    1) National Cancer Institute Trends Progress Report-2009/2010 Updated 2) NCI SEER Prostate Cacner Statistics 2012  3) Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Epstein et al Am J Surg Pathol. 2001 Aug;25(8):1079-85 3) Rui Henrique, Carmen Jerónimo, Manuel R. Teixeira, et al., Epigenetic Heterogeneity of High-Grade Prostatic Intraepithelial Neoplasia: Clues for Clonal Progression in Prostate Carcinogenesis, Mol Cancer Res 2006;4:1-8 4) Trock, B. J., Brotzman, M. J., Mangold, L. A., Bigley, J. W., Epstein, J. I., McLeod, D., Klein, E. A., Jones, J. S., Wang, S., McAskill, T., Mehrotra, J., Raghavan, B. and Partin, A. W. (2011), Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU International. doi: 10.1111/j.1464-410X.2011.10718.x 5) Stewart et al., abstract LBA6, page 211, proceeding of the AUA Annual Meeting, May 2012, Atlanta, GA.